Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1997 1
1998 1
1999 1
2001 1
2002 1
2004 2
2005 1
2006 2
2007 2
2008 6
2009 7
2010 6
2011 7
2012 10
2013 7
2014 8
2015 12
2016 8
2017 13
2018 23
2019 18
2020 27
2021 36
2022 24
2023 20
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Konispoliatis
Page 1
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Clinical effectiveness of Invisalign® orthodontic treatment: a systematic review.
Papadimitriou A, Mousoulea S, Gkantidis N, Kloukos D. Papadimitriou A, et al. Prog Orthod. 2018 Sep 28;19(1):37. doi: 10.1186/s40510-018-0235-z. Prog Orthod. 2018. PMID: 30264270 Free PMC article.
In general, the level of evidence was moderate and the risk of bias ranged from low to high, given the low risk of bias in included RCTs and the moderate (n = 13) or high (n = 6) risk of the other studies. The lack of standardized protocols and the high amount of cl …
In general, the level of evidence was moderate and the risk of bias ranged from low to high, given the low risk of bias in included RCTs and …
Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
Leventogiannis K, Kyriazopoulou E, Antonakos N, Kotsaki A, Tsangaris I, Markopoulou D, Grondman I, Rovina N, Theodorou V, Antoniadou E, Koutsodimitropoulos I, Dalekos G, Vlachogianni G, Akinosoglou K, Koulouras V, Komnos A, Kontopoulou T, Prekates A, Koutsoukou A, van der Meer JWM, Dimopoulos G, Kyprianou M, Netea MG, Giamarellos-Bourboulis EJ. Leventogiannis K, et al. Cell Rep Med. 2022 Nov 15;3(11):100817. doi: 10.1016/j.xcrm.2022.100817. Cell Rep Med. 2022. PMID: 36384100 Free PMC article. Clinical Trial.
36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016.
Bateman RM, Sharpe MD, Jagger JE, Ellis CG, Solé-Violán J, López-Rodríguez M, Herrera-Ramos E, Ruíz-Hernández J, Borderías L, Horcajada J, González-Quevedo N, Rajas O, Briones M, Rodríguez de Castro F, Rodríguez Gallego C, Esen F, Orhun G, Ergin Ozcan P, Senturk E, Ugur Yilmaz C, Orhan N, Arican N, Kaya M, Kucukerden M, Giris M, Akcan U, Bilgic Gazioglu S, Tuzun E, Riff R, Naamani O, Douvdevani A, Takegawa R, Yoshida H, Hirose T, Yamamoto N, Hagiya H, Ojima M, Akeda Y, Tasaki O, Tomono K, Shimazu T, Ono S, Kubo T, Suda S, Ueno T, Ikeda T, Hirose T, Ogura H, Takahashi H, Ojima M, Kang J, Nakamura Y, Kojima T, Shimazu T, Ikeda T, Suda S, Izutani Y, Ueno T, Ono S, Taniguchi T, O M, Dinter C, Lotz J, Eilers B, Wissmann C, Lott R, Meili MM, Schuetz PS, Hawa H, Sharshir M, Aburageila M, Salahuddin N, Chantziara V, Georgiou S, Tsimogianni A, Alexandropoulos P, Vassi A, Lagiou F, Valta M, Micha G, Chinou E, Michaloudis G, Kodaira A, Ikeda T, Ono S, Ueno T, Suda S, Izutani Y, Imaizumi H, De la Torre-Prados MV, Garcia-De la Torre A, Enguix-Armada A, Puerto-Morlan A, Perez-Valero V, Garcia-Alcantara A, Bolton N, Dudziak J, Bonney S, Tridente A, Nee P, Nicolaes G, Wiewel M, Schultz M, Wildhag… See abstract for full author list ➔ Bateman RM, et al. Crit Care. 2016 Apr 20;20(Suppl 2):94. doi: 10.1186/s13054-016-1208-6. Crit Care. 2016. PMID: 27885969 Free PMC article.
Herrera-Ramos, J. Ruiz-Hernandez, L. Borderias, J. Horcajada, N. Gonzalez-Quevedo, O. Rajas, M. Briones, F. Rodriguez de Castro, C. Rodriguez Gallego P003 - Brain protective effects of intravenous immunoglobulin through inhibition of complement activation and apoptosis in …
Herrera-Ramos, J. Ruiz-Hernandez, L. Borderias, J. Horcajada, N. Gonzalez-Quevedo, O. Rajas, M. Briones, F. Rodriguez de Castro, C. R …
Diabetic keratopathy: Insights and challenges.
Priyadarsini S, Whelchel A, Nicholas S, Sharif R, Riaz K, Karamichos D. Priyadarsini S, et al. Surv Ophthalmol. 2020 Sep-Oct;65(5):513-529. doi: 10.1016/j.survophthal.2020.02.005. Epub 2020 Feb 22. Surv Ophthalmol. 2020. PMID: 32092364 Free PMC article. Review.
Corneal injury: Clinical and molecular aspects.
Barrientez B, Nicholas SE, Whelchel A, Sharif R, Hjortdal J, Karamichos D. Barrientez B, et al. Exp Eye Res. 2019 Sep;186:107709. doi: 10.1016/j.exer.2019.107709. Epub 2019 Jun 22. Exp Eye Res. 2019. PMID: 31238077 Free PMC article. Review.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
FINDINGS: Between Oct 17, 2018, and Oct 26, 2021, 2057 adult patients were randomly allocated across both studies (72 mg ligelizumab n=614; 120 mg ligelizumab n=616; 300 mg omalizumab n=618, and placebo n=209). ...
FINDINGS: Between Oct 17, 2018, and Oct 26, 2021, 2057 adult patients were randomly allocated across both studies (72 mg ligelizumab n …
Modeling Psychiatric Disorder Biology with Stem Cells.
Das D, Feuer K, Wahbeh M, Avramopoulos D. Das D, et al. Curr Psychiatry Rep. 2020 Apr 21;22(5):24. doi: 10.1007/s11920-020-01148-1. Curr Psychiatry Rep. 2020. PMID: 32318888 Free PMC article. Review.
Corrigendum.
[No authors listed] [No authors listed] Gynecol Endocrinol. 2015 Oct;31(10):833. doi: 10.3109/09513590.2015.1108275. Gynecol Endocrinol. 2015. PMID: 26559694
Bakas, P., Boutas, I., Creatsa, M., Vlahos, N., Gregoriou, O., Creatsas, G., and Hassiakos, D. (2015). Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation? ...When the above article was first published onlin …
Bakas, P., Boutas, I., Creatsa, M., Vlahos, N., Gregoriou, O., Creatsas, G., and Hassiakos, D. (2015). Can anti-Mullerian hormone (AM …
215 results